Funding catalogue
A curated catalogue of government grants funding psychedelic research and drug development — covering US agencies (NIH, NIDA, NIMH, DoD, VA, NSF) and international funders (EU Horizon, UKRI, Swiss SNSF, and others). Each entry links to its primary source and to the recipient's profile on Blossom.
| Year | Funder | Recipient | Amount | Title | Source |
|---|---|---|---|---|---|
| 2025 | US Advanced Research Projects Agency for Health (ARPA-H) | Diamond Therapeutics | $2,000,000 | ARPA-H EVIDENT — Psilocybin for generalized anxiety disorder (Phase 2a data) | Source ↗ |
| 2025 | US Advanced Research Projects Agency for Health (ARPA-H) | Duke University | $2,000,000 | ARPA-H EVIDENT — Stress physiology biomarkers for behavioral health | Source ↗ |
| 2025 | Congressionally Directed Medical Research Programs | Emory University | $4,900,000 | DoD — MDMA-assisted therapy + massed prolonged exposure for active-duty PTSD | Source ↗ |
| 2025–2028 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Psilera | $2,000,000 | NIAAA SBIR — Novel neuroplastogen for alcohol use disorder | Source ↗ |
| 2025 | US Advanced Research Projects Agency for Health (ARPA-H) | University of Wisconsin-Madison | $2,000,000 | ARPA-H EVIDENT — Conscious vs non-conscious mechanisms of psilocybin therapy | Source ↗ |
| 2025 | Congressionally Directed Medical Research Programs | Walter Reed National Military Medical Center | $4,900,000 | DoD — MDMA-assisted therapy for active-duty PTSD (Walter Reed cohort) | Source ↗ |
| 2025 | National Institute on Drug Abuse (NIDA) | atai Life Sciences | $11,400,000 | NIDA UG3/UH3 — Non-hallucinogenic 5-HT2A/2C agonists for opioid use disorder | Source ↗ |
| 2024 | National Institute on Drug Abuse (NIDA) | Gilgamesh Pharma | $14,000,000 | NIDA — GM-3009 ibogaine analog for opioid use disorder | Source ↗ |
| 2024–2029 | National Institute on Drug Abuse (NIDA) | NYU Center for Psychedelic Medicine | $15,000,000 | NIDA — Psilocybin for opioid use disorder (landmark $15M trial) | Source ↗ |
| 2024 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NYU Center for Psychedelic Medicine | $3,800,000 | NIAAA — Psilocybin for alcohol use disorder (Phase 2 fMRI mechanistic trial) | Source ↗ |
| 2024–2028 | European Commission (Horizon Europe) | University Medical Center Groningen | €6,500,000 | Horizon Europe — PsyPal: psilocybin therapy in palliative care | Source ↗ |
| 2024–2029 | National Institute on Drug Abuse (NIDA) | University of California San Diego | $2,400,000 | NIDA — Non-classic psychedelics for methamphetamine use disorder | Source ↗ |
| 2024–2029 | U.S. Department of Veterans Affairs (VA) | Yale University | $1,500,000 | VA — MDMA-assisted therapy for PTSD + alcohol use disorder in veterans | Source ↗ |
| 2023–2027 | National Center for Complementary and Integrative Health (NCCIH) | Johns Hopkins Center for Psychedelic and Consciousness Research | $1,518,560 | NCCIH R33AT012317 — Psilocybin and affective function in chronic low-back pain + depression | Source ↗ |
| 2022–2027 | Medical Research Future Fund (MRFF) | Monash University | A$2,700,000 | MRFF — Psilocybin-assisted psychotherapy for treatment-resistant depression | Source ↗ |
| 2022–2027 | National Cancer Institute (NCI) | NYU Center for Psychedelic Medicine | $2,627,155 | NCI R01CA268521 — Psilocybin for cancer-related psychiatric and existential distress | Source ↗ |
| 2022–2027 | Medical Research Future Fund (MRFF) | University of Sydney | A$1,900,000 | MRFF — MDMA-assisted treatment for PTSD + alcohol use disorder | Source ↗ |
| 2021–2024 | National Institute on Drug Abuse (NIDA) | Johns Hopkins Center for Psychedelic and Consciousness Research | $4,000,000 | NIDA U01DA052174 — Multisite psilocybin trial for smoking cessation | Source ↗ |
| 2021 | National Institute of Mental Health (NIMH) | Yale University | $800,000 | NIMH K-award — Psilocybin for treatment-resistant OCD (Kelmendi) | Source ↗ |
| 2017–2022 | National Institute on Drug Abuse (NIDA) | Johns Hopkins Center for Psychedelic and Consciousness Research | $3,960,000 | NIDA R01 DA042103 — Psilocybin facilitation of smoking cessation | Source ↗ |
| 2014–2017 | Medical Research Council | Imperial College London | Amount undisclosed | MRC — Psilocybin for treatment-resistant depression (feasibility trial) | Source ↗ |